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Background: Uric acid has antioxidant effects on neurons. Abnormally high levels of uric acid are, however, associated
with gout. Previous studies have suggested that high levels of uric acid (and the presence of gout) may exert a protective
effect against the risk of developing some neurological diseases. We aimed to investigate this hypothesis in a large
database of hospital admissions in England.
Methods: We analysed a database of linked statistical records of hospital admissions and death registrations in England
(1999–2012). A cohort of people with gout was constructed and followed for development of multiple sclerosis (MS),
Parkinson’s disease (PD) or motor neuron disease (MND). Then, conversely, cohorts of all people in the database with MS,
PD or MND were constructed and followed for subsequent gout. Rate ratios (RRs) were determined, comparing these
cohorts with people in a reference cohort.
Results: In the gout cohort, we observed a modest elevation of the overall risk of subsequent MS, PD and MND
(respectively, RR = 1.27 (95% confidence interval 1.03-1.55), 1.11 (1.05-1.17) and 1.28 (1.11-1.48) which was largely attributable
to an increased risk observed in the early years after hospitalisation for gout. The increased risk of neurological disease did
not remain after 5 years. In the cohorts of people with MS or PD, there was a significantly reduced risk of subsequent gout
admission (RR = 0.79 (0.69-0.89) and 0.83 (0.79-0.87), respectively). This inverse association was sustained over time. There
was also a reduced risk of MND following gout which only emerged more than five years following initial gout admission
(RR at 5+ years 0.35 (0.15-0.68)).
Conclusions: This study investigated the epidemiological evidence for a protective role of high serum concentration of
uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND. Our observations do not support this
hypothesis. However, when the order was reversed, and we retrospectively followed up patients with MS, PD and MND for
a number of years, we found a statistically significant deficit of gout. This suggests that there is relationship between some
aspects of these neurodegenerative diseases and metabolism of uric acid.
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Oxidative stress is thought to have an important role in
neuronal degeneration. Neuronal degeneration is a char-
acteristic feature of several neurological disorders in-
cluding multiple sclerosis (MS), Parkinson’s disease
(PD), and motor neuron disease (MND) [1,2]. A high
fatty acid content and a low antioxidant capacity are* Correspondence: michael.goldacre@dph.ox.ac.uk
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unless otherwise stated.thought to be factors which render neural cells more
susceptible than other body tissues to oxidative stress.
This, in turn, may result in damage to proteins and
DNA, subsequent inflammation and neuronal loss [3-5].
Uric acid is a potent antioxidant found throughout
extracellular fluid, as sodium urate, and is thought to ac-
count for more than half of the antioxidant capacity of
plasma [6]. Levels of serum urate are closely correlated
with levels of urate in the cerebrospinal fluid (CSF) and
CSF urate is typically 10% of peripheral levels. This sug-
gests that CSF levels of urate are in part dependent onl. . This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acid may have neuroprotective influence as a scavenger
of reactive nitrogen and oxygen radicals. A powerful
antioxidant effect of uric acid on neurons has been dem-
onstrated through in vivo and in vitro studies [8,9]. The
hypothesis that high levels of uric acid exert a protective
effect against oxidative neuronal damage is supported by
studies showing that individuals with PD, MS and MND
have significantly lower serum uric acid levels than healthy
controls [10-12]; and there is some evidence that low uric
acid levels correlate with progression of symptoms and
disease relapse [13,14]. Among men participating in a 30-
year prospective study, men with elevated uric acid levels
had a 40% reduction in the incidence of PD, unaffected by
adjustment for age and smoking [15]. Similarly, a large
nested case–control study found that higher plasma con-
centrations of urate predict risk of PD, with a signifi-
cantly reduced rate of PD for men in the highest quartile
of uricemia compared with the lowest [16]. This notion
is strengthened by the finding that a diet which increases
plasma urate levels is associated with a reduced PD risk,
rendering it unlikely that the association is merely a con-
sequence of shared predisposing factors [17].
Abnormally high levels of serum uric acid are, however,
known to be pathological and most commonly associated
with gout, a form of recurrent acute inflammatory arthritis
in which uric acid crystallizes and is deposited within
joints [18]. Individuals with gout, and therefore high levels
of serum uric acid, have been postulated to have greater
protection from neurodegenerative diseases in which oxi-
dative stress is thought to contribute to pathogenesis. A
lower risk of PD and MS in individuals with gout has been
previously reported [19-21]. The relationship between gout
(as an indicator of high levels of uric acid) and the inci-
dence of neurodegenerative diseases is of potential thera-
peutic interest given the proposed possibility that elevation
of uric acid levels may reduce the incidence of neuro-
logical disease. However, it is currently unclear if lower
levels of uric acid in individuals with MS, PD and MND
represent a cause or consequence of the disease. This rec-
ord linkage study therefore aimed to extend previous
findings by determining the risk of PD, MS and MND in
individuals with a history of gout, and, conversely, the risk
of subsequent gout in individuals with PD, MS or MND.
Methods
Population and data
We used a linked English national data set of hospital
admissions (Hospital Episode Statistics (HES) and mor-
tality. HES data are records of hospital care that are
compiled for every episode of hospital day case care
(when the patient is admitted to hospital but does not
stay overnight) or hospital inpatient care in all English
National Health Service (NHS) hospitals, and they weresupplied by the English national Information Centre for
Health and Social Care. The mortality data, derived
from death registrations, were supplied by the Office for
National Statistics. The linked dataset used in this study,
in which successive records for each individual were
linked together, was constructed by the Oxford record
linkage group. The International Classification of Disease
(ICD) codes used for gout were 274 in the ninth revision
and M10 in the tenth. The ICD 9 and 10 revision codes
used for MS, PD, and MND were, respectively, 340 and
G35, 332.0 and G20, and 335.2 and G12.2.
Gout before MS, PD, or MND
The methods of analysis were the same for all neuro-
logical diseases; we describe the methods for gout
followed by MS as the example. A cohort of people with
gout (the ‘exposure’ cohort) was constructed for people
with a diagnosis of gout in an episode of hospital care by
identifying the first episode of day case care, or admis-
sion, for gout during the study period. A reference co-
hort was constructed by identifying the first admission
for each individual with various other mainly minor
medical and surgical conditions as described in previous
studies of disease associations [22]. Standard epidemio-
logical practice was followed by selecting a diverse range
of conditions rather than relying on a limited range (in
case the latter are themselves atypical in their risk of
neurological disease). As a check, we estimated the risk
of each neurological disease in the reference cohort to
ensure that it does not include conditions that have
atypically high or low rates of neurological disease.
People were included in the gout or reference cohort
if they did not have an admission for MS either before
or at the same time as the admission for gout or the ref-
erence condition. The database was then investigated for
any subsequent NHS hospital care for, or death from,
MS in these cohorts (the ‘outcome’ condition). We con-
sidered that rates of MS in the reference cohort would
approximate those in the general population while
allowing for migration (data on migration by individuals
covered by the datasets was not available).
Statistical methods
Rates of MS were calculated based on person-days. Date
of entry into each cohort was the date of first admission
for gout, or reference condition, from the start of data
collection on 1st January1999 and date of exit was the
date of first record of MS, death, or the end of data col-
lection (31st March 2012), whichever was the earliest.
We calculated rates for MS, stratified and then standar-
dised by age (in five-year age groups), sex, calendar year of
first recorded admission, region of residence, and quintile
of patients’ Index of Deprivation score (a standard English
measure of socio-economic status). The indirect method
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reference cohorts as the standard population. We applied
the stratum–specific rates (e.g. within each five-year age
stratum) in the standard population to the number of
people in each stratum (e.g. within the same five-year age
stratum) in the gout cohort and then, separately, to those
in the same stratum in the reference cohort, to obtain the
expected number of people with MS in each stratum of
the gout and reference cohort. Observed and expected
numbers were then summed across all strata to give totals
for all strata combined. Rate ratios (RRs) were calculated
by taking the standardised rate of occurrence of MS in the
gout cohort relative to the reference cohort using the for-
mula (Ogout / Egout) / (Oref / Eref ), where O and E are the
observed and expected numbers of MS cases in the gout
and reference cohorts, respectively. The 95% confidence
interval (95% CI) for the rate ratio of MS and χ2 statistics
for its significance were calculated, with continuity correc-
tion for small numbers, as described elsewhere [23].MS, PD, and MND before gout
We then used the same methods to study the neurological
diseases followed by gout. We constructed ‘exposure’ co-
horts of people, separately, comprising all people in the
dataset with MS, PD, or MND. We compared them with
the reference cohort. In this analysis, we excluded anyone
with gout prior to or at the same time as their first admis-
sion for neurological disease or reference cohort condi-
tion. Taking both study designs – gout followed by
neurological disease, and neurological disease followed by
gout – the exclusions ensured that no individual was
double-counted as a case of gout both before and after
neurological disease.
The datasets are in the custodianship of the Unit of
Health-Care Epidemiology and are not freely available.
Ethical approval to construct, maintain, develop and
analyse the datasets has been obtained, on an ongoing
basis, from the Central and South Bristol Multi–Centre




Age (%) Male (%) Age (%) Male (%)
<25 0.1 76.7 2.1 30.4
25-44 4.9 92.4 29.1 29.3
45-54 9.0 91.1 25.6 29.7
55-64 15.7 86.9 21.9 33.7
65-74 23.9 78.5 13.3 32.6
75+ 46.3 61.4 8.1 28.2
Total 100 73.7 100 30.8Results
Gout before MS, PD or MND
Basic demographic information of the disease cohorts is
shown in Table 1. The number of people admitted to
hospital with gout was 214,653. There were approxi-
mately 9 million people in the reference cohort. Com-
paring the gout cohort with the reference cohort, the
rate ratios (RR) for subsequent MS, PD and MND were,
respectively, 1.27 (95% confidence interval 1.03-1.55),
1.11 (1.05-1.17) and 1.28 (1.11-1.48), Table 2. Results
were no longer significant upon inclusion only of cases
of neurological disease which occurred at least five years
following initial gout admission (Table 2).
There were 82,220, 217,179 and 25,185 people, re-
spectively, in the MS, PD and MND cohorts. In the co-
horts of people with MS, PD and MND, the RRs for
subsequent gout were, respectively, 0.79 (0.69-0.89), 0.83
(0.79-0.87) and 0.94 (0.75-1.16), Table 3. Notably, a re-
duced risk of MS and PD following gout was significant
after the first year following admission for gout, and was
then sustained long-term. For example, after 5 years fol-
lowing hospitalisation for MS the rate ratio for gout was
0.70 (0.57-0.85) and after hospitalisation for PD 0.52
(0.45-0.59). The risk for gout was not different between
the reference cohort and people hospitalised with MND
within five years after hospitalisation for MND, but it
was significantly and strikingly low at 5 years and more
after hospitalisation (RR 0.35, 0.15-0.68), Table 3.
Discussion
In the gout cohort, we demonstrated a statistically sig-
nificant but modest elevation of risk of admission for
subsequent MS, PD and MND. After excluding cases of
MS, PD or MND observed in the first year after hospi-
talisation with gout, there was no elevated RR for these
conditions. These results do not confirm findings from
previous studies suggesting a reduced risk of neurological
disease following gout as a consequence of a neuroprotec-
tive antioxidant effect of uric acid, or the corollary that
individuals with low levels of uric acid have an impairedParkinson’s disease Motor neuron disease
Age (%) Male (%) Age (%) Male (%)
0 53.7 1.6 64.0
0.5 57.8 4.1 64.9
1.5 61.9 8.0 63.0
6.2 63.7 19.3 59.9
22.8 61.3 31.6 56.8
68.9 53.6 35.4 53.0
100 56.2 100 57.0
Table 2 Occurrence of multiple sclerosis (MS), Parkinson’s disease (PD) and motor neuron disease (MND) in patients
hospitalised with gout by time interval: observed (O) and expected (E) number of cases in each cohort, relative risk
(RR) with 95% confidence intervals (95% CI) in the exposure cohort compared with the reference cohorta
Time
interval
Gout before MS Gout before PD Gout before MND
O E RR (95% CI) O E RR (95% CI) O E RR (95% CI)
Overall 98 77.3 1.27 (1.03-1.55) 1568 1420.3 1.11 (1.05-1.17) 197 155.1 1.28 (1.11-1.48)
<1 yr 36 23.5 1.55 (1.08-2.15) 405 330.9 1.24 (1.12-1.38) 59 39.0 1.56 (1.17-2.04)
1-4 yrs 39 36.9 1.06 (0.75-1.45) 824 745.8 1.11 (1.03-1.19) 95 80.4 1.19 (0.96-1.46)
5+ yrs 23 16.8 1.37 (0.87-2.06) 339 343.6 0.99 (0.88-1.10) 43 35.6 1.21 (0.87-1.64)
aConditions used in reference cohort, with Office of Population, Censuses and Surveys (OPCS) code edition 4 for operations and ICD10 code for diagnosis (with
equivalent codes used for other coding editions): adenoidectomy (OPCS4 E20), appendectomy (H01–H03), dilation and curettage (Q10–Q11), hip replacement
(W37–W39), knee replacement (W40– W42), cataract (H25), otitis (H60-H67), upper respiratory tract infections (J00-J06), varicose veins (I83), haemorrhoids (I84),
deflected septum (J34.2), nasal polyp (J33), impacted tooth and other disorders of teeth (K00–K03), inguinal hernia (K40), in-growing nail, toenail and other diseases of
nails (L60), bunion (M20.1), internal derangement of knee (M23), selected limb fractures (S42, S52, S62, S82, S92), contraceptive management (Z30).
Note that, in analysis, we included all people eligible to be in the reference cohort in each stratum and calculated the observed and expected number of people
within each age stratum (see Method). Then, given that the individual stratum-specific values of observed and expected cases were equivalent in respect of age,
we summed the age-specific values to provide an age-standardised all-ages set of RRs.
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possible that the inflammatory state associated with the
development of symptomatic gout or recurrent inflam-
matory arthritis (rather than simply hyperuricemia in
previous work) counteracts any potential protective
antioxidant effect of uric acid. The observed slightly in-
creased risk in early years might be a reflection of sur-
veillance bias, whereby an individual seen in hospital for
one condition is more likely to have a second detected.
Another possible explanation for the small increase in
risk in the early years, that was not sustained long-term,
is that individuals admitted to hospital with gout may
undertake measures successfully to lower their levels of
uric acid (and reduce future gout attacks), which may
involve both dietary changes and the use of uric acid re-
ducing medication [24]. Further investigation of the
comparison of risk of MS, PD or MND in treated vs un-
treated hyperuricemia would have enabled better char-
acterisation of the association, but such data was not
available in this study.
Further, from hospital admission statistical records
alone, we cannot be sure that, in the gout cohort, the
onset of gout really did invariably precede the onset of
MS, PD and MND. The date of first admission for aTable 3 Occurrence of gout in patients hospitalised with mul
neuron disease (MND) by time interval: observed (O) and exp
(RR) with 95% confidence intervals (95% CI) in the exposure
MS before gout PD befor
Time interval O E RR (95% CI) O
Overall 246 311.7 0.79 (0.69-0.89) 1521
<1 yr 50 43.1 1.16 (0.86-1.53) 522
1-4 yrs 96 126.4 0.76 (0.61-0.93) 728
5+ yrs 100 142.2 0.70 (0.57-0.85) 231
See footnotes Table 2.neurodegenerative disease is likely to have been pre-
ceded by a period of sub-clinical/undiagnosed disease,
and thus, the disease state itself may have resulted in
somewhat elevated levels of uric acid and an increased
risk of gout. The fact that the raised risk was not sus-
tained over time means that we cannot be confident that
the findings support a causal role for uric acid in altering
neurological disease risk. It needs further investigation
to establish whether uric acid levels alter neurological
disease risk (and/or disease progression), given the po-
tential therapeutic approach of altering uric acid levels
(through either dietary or pharmacological measures) in
altering risk of neurological diseases.
In the MS, PD and MND cohorts, we found a prolonged
reduced risk of subsequent admission for gout. Notably,
for the MS and PD cohorts a reduced risk of gout was
seen following the first year of initial admission for neuro-
logical disease. In the MND cohort, this reduced risk only
appeared five years following initial MND admission. Al-
though, we can only speculate about pathophysiological
mechanisms, our findings on gout before and after the
neurological diseases might indicate that the causal path-
way is that the neurological disease states result in lowered
uric acid levels. For example, central nervous systemtiple sclerosis (MS), Parkinson’s disease (PD) and motor
ected (E) number of cases in each cohort, relative risk
cohort compared with the reference cohort
e gout MND before gout
E RR (95% CI) O E RR (95% CI)
1825 0.83 (0.79-0.87) 83 88.4 0.94 (0.75-1.16)
489 1.07 (0.98-1.17) 41 29.9 1.38 (0.99-1.87)
893.2 0.85 (0.79-0.92) 34 35.5 0.96 (0.66-1.34)
442.8 0.52 (0.45-0.59) 8 23.0 0.35 (0.15-0.68)
Pakpoor et al. BMC Neurology  (2015) 15:16 Page 5 of 6inflammation which is a typical feature of MS has been as-
sociated with increased production of the strong oxidant
peroxynitrite and free radicals, which may in turn lead to
reduced levels of uric acid, which is a peroxynitrite scaven-
ger [25]. A cross-sectional study which found markedly re-
duced levels of serum urate in MND patients with bulbar
onset, and with a longer duration of disease, suggested that
the reduced levels of serum urate may be a consequence of
malnutrition secondary to the impact of MND, particularly
in its later stages [26].
This study’s strengths include its large size and the fact
that it is a national study and therefore generalizable as
the cohorts are likely to relatively accurately reflect the
national prevalence of these neurological disorders. Fur-
ther, it demonstrates what can be done with the analysis
of readily available electronic medical records.
The study also has limitations. Importantly, it is not a
cohort study with follow-up from the date of “first ever”
diagnosis, but just from “first recorded” diagnosis in a hos-
pital day case or inpatient record. Data are not available
on patients who migrate out of England. The dataset is
limited to people who were admitted to hospital, or who
received day case specialist care, and thus there exists the
potential for selection bias in omitting milder cases of
gout. Further, given that only a minority of individuals
with elevated uric acid levels develop gout, using gout as a
proxy for high uric acid levels may underestimate the as-
sociation between uric acid and neurological diseases. Uric
acid levels appear positively correlated with risk of gout,
and the gout cohort is therefore more likely to capture
those with more severe uric acid elevation in which, over
time, urate crystals have deposited in or around joints.
There is very limited information on potential confound-
ing factors such as detailed socioeconomic characteristics,
beyond the IMD index, ethnicity and smoking.
Studies of alternative design would be costly and com-
plex undertakings. For example, if funds allowed, “shoe-
leather” studies of individual patients could be undertaken
by personal follow-up, such as following large numbers of
people with gout to await development of these three un-
common neurological diseases, or studies could be under-
taken of people with MS, PD or MND to identify clinical
gout or to measure their serum uric acid levels. The latter
would need to be designed in ways that allow the investi-
gators to determine the time sequence of ‘high levels of
uric acid before the neurological condition’ or ‘neuro-
logical condition before changes in uric acid levels’.
Conclusions
In summary, the data in our study provide good evi-
dence of an inverse association between gout and MS
PD, and MND. Our data therefore supports the notion
that the pre-existence of the neurological diseases re-
duces the occurrence of gout. We highlight the need forfuture studies to incorporate duration of disease, and ef-
fects of treatment, with longitudinal data on uric acid
levels to determine whether altered uric acid levels, asso-
ciated with neurodegenerative disease, are truly a cause
or a consequence of neurodegenerative disease.
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